Drug Type Autologous CAR-T |
Synonyms- |
Target |
Action modulators |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), CD79B modulators(B-cell antigen receptor complex-associated protein beta chain modulators), Immunologic cytotoxicity |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Follicular Lymphoma | Phase 1 | United States | 26 Oct 2023 | |
| High grade B-cell lymphoma | Phase 1 | United States | 26 Oct 2023 | |
| Mantle-Cell Lymphoma | Phase 1 | United States | 26 Oct 2023 | |
| Marginal Zone B-Cell Lymphoma | Phase 1 | United States | 26 Oct 2023 | |
| Mediastinal large B-cell lymphoma | Phase 1 | United States | 26 Oct 2023 | |
| Non-Hodgkin's lymphoma refractory | Phase 1 | United States | 26 Oct 2023 | |
| Recurrent Non-Hodgkin Lymphoma | Phase 1 | United States | 26 Oct 2023 |





